Bridgeway Capital Management LLC Sells 5,400 Shares of Pulmonx Co. (NASDAQ:LUNG)

Bridgeway Capital Management LLC decreased its holdings in Pulmonx Co. (NASDAQ:LUNG) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,900 shares of the company’s stock after selling 5,400 shares during the period. Bridgeway Capital Management LLC owned 0.16% of Pulmonx worth $427,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in LUNG. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Pulmonx by 44.8% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,941 shares of the company’s stock valued at $570,000 after acquiring an additional 25,988 shares during the period. SG Americas Securities LLC grew its holdings in Pulmonx by 27.0% during the 4th quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after purchasing an additional 3,310 shares during the last quarter. JPMorgan Chase & Co. raised its position in Pulmonx by 2.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock worth $8,750,000 after purchasing an additional 25,002 shares during the period. Renaissance Technologies LLC lifted its stake in Pulmonx by 38.7% in the fourth quarter. Renaissance Technologies LLC now owns 220,510 shares of the company’s stock worth $1,497,000 after purchasing an additional 61,500 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Pulmonx by 1.8% during the third quarter. Barclays PLC now owns 94,109 shares of the company’s stock valued at $780,000 after buying an additional 1,679 shares during the period. Institutional investors own 91.04% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on LUNG. Morgan Stanley began coverage on Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating on the stock. Jefferies Financial Group assumed coverage on Pulmonx in a research report on Monday, March 10th. They set a “buy” rating for the company. Piper Sandler reissued an “overweight” rating and set a $9.00 target price (down from $10.00) on shares of Pulmonx in a research note on Thursday, May 1st. Canaccord Genuity Group reduced their price target on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Finally, Citigroup assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Pulmonx has a consensus rating of “Moderate Buy” and an average price target of $12.07.

Insider Transactions at Pulmonx

In other news, CFO Mehul Joshi sold 14,384 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.12, for a total transaction of $102,414.08. Following the sale, the chief financial officer now owns 113,986 shares in the company, valued at approximately $811,580.32. The trade was a 11.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven S. Williamson sold 27,689 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.14, for a total transaction of $197,699.46. Following the transaction, the chief executive officer now owns 194,342 shares in the company, valued at approximately $1,387,601.88. This trade represents a 12.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 145,660 shares of company stock valued at $1,128,484 in the last 90 days. Insiders own 6.80% of the company’s stock.

Pulmonx Stock Up 9.2%

Pulmonx stock opened at $3.68 on Tuesday. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The firm has a market cap of $148.15 million, a P/E ratio of -2.56 and a beta of 0.65. The business has a fifty day moving average of $5.83 and a two-hundred day moving average of $6.42. Pulmonx Co. has a twelve month low of $3.36 and a twelve month high of $9.41.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $22.54 million during the quarter, compared to analysts’ expectations of $22.03 million. On average, analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.